MVA-VLP malaria vaccine

**MVA-VLP malaria vaccine** is an investigational **multi-antigen malaria vaccine** being developed by **GeoVax** using its **GV-MVA-VLP** platform. The product uses a **recombinant modified vaccinia Ankara viral vector** engineered to express malaria antigens that assemble into **virus-like particle immunogens in vivo**, with the goal of inducing durable functional antibody responses together with **CD4+ and CD8+ T-cell immunity**. GeoVax has described these candidates as targeting **multiple stages of the malaria parasite life cycle** for malaria prevention, and company disclosures indicate constructs based on **Plasmodium falciparum** antigens including **circumsporozoite protein** and **Pfs230** in patented VLP-MVA designs. The program appears to remain preclinical or otherwise early-stage, with public emphasis on platform development, patent protection, and collaboration with groups such as NIH, USAID, and the Burnet Institute.

Other names

GeoVax MVA-VLP malaria vaccineMVA-VLP malaria vaccine candidates